Business
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
Phio's INTASYL compound targets aging skin disorders Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Phio's INTASYL compound targets aging skin disorders\nMarlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that they have entered into an exploratory collaboration regarding opportunities for the recently issued Phio patent for cosmeceutical skin care applications.\nThe collaborating company is one of the leading companies in luxury skin care products that are commercialized world-wide.\n\"This is a significant step in demonstrating the potential versatility of INTASYL across multiple applications,\" said Robert Bitterman, CEO of Phio Pharmaceuticals. \"The INTASYL patent portfolio now consists of 77 issued patents for silencing over 25 gene targets in the fields of dermatology, immuno-oncology, ophthalmology, and viral disorders, both intratumorally and in adoptive cell therapy.\"\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for specialized formulations or drug delivery systems. INTASYL drugs precisely down regulate specific proteins that inhibit the body's ability to overcome chronic diseases and other disorders.\nFor additional information, visit the Company's website, www.phiopharma.com.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\" \"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\" \"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in ...